stockrow
Saturday 7 November 2026
Export DSGN’s income statement to Excel — free account
Design Therapeutics, Inc.
DSGN Healthcare Biotechnology
- EPS
- −7.27%
- Free cash flow
- −7.00%
Quarter to September 2026, against a year earlier
10.19
0.52
+5.38%
Follow DSGN
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| (36.87%) | (34.13%) | (31.26%) | (30.70%) |
+8 more TTM periods Free account |
|
| (34.57%) | (32.33%) | (29.80%) | (29.18%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(36.72%) | (35.14%) | (32.03%) | (32.97%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.94) | (0.88) | (0.88) | (0.95) | |
Free Cash Flow |
(59.37) | (55.22) | (54.00) | (54.55) | |
Capital Expenditures |
(0.07) | (0.14) | — | (0.19) | |
| Other line items | |||||
Cash ROIC |
(14.45%) | (13.49%) | (12.25%) | (12.62%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.80 | 0.78 | 0.77 | 0.78 | |
Depreciation/Fixed assets |
(0.10) | (1.18) | (2.09) | (2.68) | |
Capex/Depreciation |
1.25 | 0.17 | 0.00 | 0.07 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.94) | (0.88) | (0.88) | (0.95) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026